Valuation: Scancell Holdings plc

Market Cap 153M 204M 179M 165M 291M 19.5B 295M 1.97B 768M 9.57B 768M 751M 33.19B P/E 2026 *
-9.86x
P/E 2027 * -18.7x
Enterprise Value 163M 218M 191M 176M 310M 20.83B 315M 2.11B 821M 10.22B 820M 802M 35.45B EV / Sales 2026 *
131x
EV / Sales 2027 * 70.4x
Free-Float
96.34%
Yield 2026 *
-
Yield 2027 * -
1 day+0.34%
1 week-15.43%
Current month-15.43%
1 month-31.95%
3 months+28.70%
6 months+48.00%
Current year+49.49%
1 week 14
Extreme 14
18
1 month 14
Extreme 14
23
Current year 9.5
Extreme 9.5
29.5
1 year 7.86
Extreme 7.8555
29.5
3 years 7.26
Extreme 7.26
29.5
5 years 7.26
Extreme 7.26
29.5
10 years 0.11
Extreme 0.1118
29.5
Manager TitleAgeSince
Chief Executive Officer 69 27/07/2021
Chief Executive Officer 64 17/11/2024
Director of Finance/CFO 50 23/04/2026
Director TitleAgeSince
Director/Board Member 69 16/11/2010
Director/Board Member 74 22/10/2019
Director/Board Member 64 23/09/2020
Date Insider Type Main position Quantity % Market Cap.
15/09/25
Vulpes Investment Management Pte Ltd.
BuyCompany 3,150,000 0.3038%
07/08/25
Vulpes Investment Management Pte Ltd.
BuyCompany 102,236 0.0099%
03/08/25
Vulpes Investment Management Pte Ltd.
BuyCompany 4,400,000 0.4244%
Change 5-day change 1-year change 3-year change Capi.($)
+0.34%-15.43%+51.79%+12.76% 204M
+0.09%+6.23%+3.91%+10.44% 50.25B
+0.40%-1.37%+401.69%+625.15% 40.39B
-0.52%+6.57%+25.41%-5.37% 34.38B
+3.97%+6.71%+26.06%+63.36% 34.4B
-4.19%-1.84%+3.76%+32.17% 26.32B
-2.40%+1.60% - - 16.64B
+1.34%+5.68%+75.77%+141.51% 16.14B
+2.07%+2.25%+16.29%+23.55% 13.71B
+1.69%+3.09%+93.44%+99.19% 13.75B
Average +0.28%+2.02%+77.57%+111.42% 24.62B
Weighted average by Cap. +0.25%+4.02%+91.62%+141.98%

Financials

2026 *2027 *
Net sales 1.25M 1.67M 1.46M 1.35M 2.37M 159M 2.41M 16.12M 6.27M 78.17M 6.27M 6.13M 271M 2.4M 3.21M 2.81M 2.59M 4.56M 306M 4.62M 30.95M 12.05M 150M 12.04M 11.77M 520M
Net income -19.23M -25.69M -22.5M -20.72M -36.52M -2.45B -37.02M -248M -96.53M -1.2B -96.47M -94.35M -4.17B -8.24M -11M -9.63M -8.87M -15.64M -1.05B -15.85M -106M -41.34M -515M -41.31M -40.41M -1.79B
Net Debt 10.42M 13.91M 12.18M 11.22M 19.78M 1.33B 20.05M 134M 52.28M 651M 52.24M 51.1M 2.26B 15.87M 21.2M 18.57M 17.1M 30.14M 2.02B 30.55M 205M 79.67M 993M 79.62M 77.87M 3.44B
Logo Scancell Holdings plc
Scancell Holdings plc is a clinical-stage biopharmaceutical company. The Company is engaged in studying the human adaptive immune system, to generate medicines to treat unmet needs in cancer. The Company is building a pipeline of products by utilizing its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies. Its product pipeline includes Modi-1, Modi-2, SCIB1 & iSCIB1+, SCIB2, SC129, SC134, SC2811, SC27, and others. Modi-1 is the first therapeutic vaccine candidate from the Company’s Moditope platform, which targets citrullinated peptides from two different proteins which have been combined to reduce the possibility of tumor escape and have each been conjugated to a toll-like receptor (TLR) 1/2 agonist, which acts as an adjuvant. Modi-2, which targets homocitrullinated cancer antigens, is the second therapeutic vaccine candidate from the Company’s Moditope platform and has the potential to address different cancer indications to Modi-1.
Employees
60
Date Price Change Volume
07/07/26 GBX 14.80 +0.34% 164,429
06/07/26 GBX 14.75 +3.51% 2,226,300
03/07/26 GBX 14.25 -5.00% 2,562,904
02/07/26 GBX 15.00 -10.71% 3,294,950
01/07/26 GBX 16.80 -4.00% 1,615,746
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.1475GBP
Average target price
0.3100GBP
Spread / Average Target
+110.17%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SCLP Stock